Immunization Action Coalition & the Hepatitis B Coalition logo

IAC EXPRESS

Previous issues index

IAC Home page

Issue Number 48             January 21, 1999

CONTENTS OF THIS ISSUE

  1. Epivir-HBV (lamivudine) is approved by the FDA as oral treatment for chronic hepatitis B

----------------------------------------------------------

Back to Top

(1)
January 21, 1999
EPIVIR-HBV (LAMIVUDINE) IS APPROVED BY THE FDA AS ORAL TREATMENT FOR CHRONIC HEPATITIS B

On December 9, 1998, the FDA approved the first oral, anti-viral medication for the treatment of adults with chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation. Epivir-HBV, a brand name for lamivudine, is available as a tablet and as an oral solution.

Epivir-HBV is manufactured by Glaxo Wellcome, Inc., based in Research Triangle Park, North Carolina.

For additional information about Epivir-HBV, read the package insert.

 

Immunization Action Coalition1573 Selby AvenueSt. Paul MN 55104
E-mail: admin@immunize.org Web: http://www.immunize.org/
Tel: 651-647-9009Fax: 651-647-9131

This page was updated on January 21, 1999